Alvotech: Steady Progress Offers A Good Chance Of Upside

iQoncept Investment Overview - Recap on Alvotech My last coverage of Alvotech (NASDAQ:ALVO) for Seeking Alpha was back in April, a few weeks before the biosimilar medicine specialist announced its Q1 2024 earnings. I gave its stock a "Buy" rating, concluding that: if you are an investor looking to gain exposure to the biosimilar industry today, Alvotech represents one of your better options, in my view. It is cheaper to own a chunk of Alvotech than most other generic drug manufacturer's I can think of - Te ...